Country for PR: United Kingdom
Contributor: PR Newswire Europe
Wednesday, March 07 2018 - 01:45
Shivom Partnership With Genetic Technologies Will Enable Better Cancer Prediction and Prevention Through Mass Genomic Data Analysis
MUNICH, March 7, 2018 /PRNewswire-AsiaNet/ --

     Blockchain Genomics Pioneer Joins Forces with Nasdaq-Listed Molecular 
Diagnostics Company To Accelerate Cancer Detection Through 'Critical Mass' of 
Genomics Data

    Shivom [ ], the blockchain-powered global 'Unique ID' 
genomic database platform, has today announced a major partnership with leading 
molecular diagnostics company Genetic Technologies [ ] 
Limited (ASX: GTG; NASDAQ: GENE) to accelerate the prediction of cancer for 
millions of individuals worldwide.

    GTG, whose lead product is BREVAGenplus(R) - a clinically validated risk 
assessment test for non-hereditary breast cancer - is at the forefront of 
preventive medicine. However, collecting data to develop the BREVAGenplus(R) 
tests has to date taken over seven years and the company's partnership with 
Shivom will massively reduce such timelines.

    "By bringing together the millions of individuals' genomic profiles that 
Shivom enables, with GTG's market leading tests, we will create critical mass 
that accelerates transformative disease prevention and personalized 
healthcare," said Dr. Axel Schumacher, co-founder & CEO of Shivom.

    "This sort of big data analysis and healthcare servicing is only possible 
through blockchain. The low-cost management of data that it enables, allows us 
to revolutionize how genomics is presented to the world," added Gourish Singla, 
Co-Founder & COO of Shivom.

    Shivom have created a secure global genomic ecosystem that aims to become 
the largest healthcare data-hub on the planet. Crucially it puts ownership of 
genome data back into the hands of individuals. Via its 'first of a kind' 
Global Genome ID, Shivom aims to revolutionize preventative healthcare, as well 
as how cures to 7,000 rare genetic diseases are discovered.

    "We believe blockchain technology will open up markets to make it much more 
efficient to catch many more users and practitioners. Not only that, by using 
the Shivom platform to its full potential, we will also be able to access the 
benefits of research in collaboration with other personalized healthcare 
organisations," commented Dr Paul Kasian, Chairman & Interim CEO of GTG.

    "Blockchain's role in this project, especially around the encryption and 
management of data, is particularly exciting for us. At present, we only use 
genomic data on a one-off basis. However, now we'll be able to use the data 
over and over again. This will be extremely valuable for GTG as we create 
genomics tests for a wide range of cancers," added Dr Kasian.

    GTG's BREVAGenPlus provides a method of assessing the risk of 
non-hereditary breast cancer in women (a cancer that 1 in every 11 women 
develops in their lifetime). The volume of unique and ethnically diverse global 
genomic data that will be available via Shivom's platform will hugely 
accelerate this process for new tests.

    About Shivom Shivom is powering the next era of genomics through blockchain 
technology - protecting identity, personalizing healthcare and transforming 
lives. A precision medicine ecosystem will offer an open web-marketplace for 
other providers to add not only genomics information, but also analytics, and 
associated apps and services to drive personalized medicine. For further 
information, please visit:

    About Genetic Technologies Limited Genetic Technologies is a molecular 
diagnostics company offering cancer predictive testing and assessment tools to 
help physicians proactively manage patient health. The Company's lead product, 
BREVAGenplus(R), is a clinically validated risk assessment test for 
non-hereditary breast cancer. For more information, please visit and

SOURCE: Shivom